| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6316441 | ALCON LABS INC | Brinzolamide and brimonidine for treating glaucoma |
Dec, 2019
(4 years ago) | |
| US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(6 years from now) | |
| US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(6 years from now) | |
Simbrinza is owned by Alcon Labs Inc.
Simbrinza contains Brimonidine Tartrate; Brinzolamide.
Simbrinza has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Simbrinza are:
- US6316441
Simbrinza was authorised for market use on 19 April, 2013.
Simbrinza is available in suspension/drops;ophthalmic dosage forms.
Simbrinza can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The generics of Simbrinza are possible to be released after 30 October, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 19, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA family patents
